Treatment News : HIV Treatment Demand in Poorer Nations to Keep Rising

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » August 2014

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

August 5, 2014

HIV Treatment Demand in Poorer Nations to Keep Rising

AIDS 2014The demand for HIV treatment in low- and middle-income nations is projected to rise to 16.8 million people by the close of 2016, aidsmap reports. The ARV Forecasting Technical Working Group presented findings from a study projecting the upswing in treatment demand at the 20th International AIDS Conference (AIDS 2014) in Melbourne, Australia.

The study, which defined treatment eligibility as 80 percent of those eligible under the 2013 treatment guidelines, projected that the demand for antiretrovirals (ARVs) will rise from 11.5 million people at the end of 2013 to 15 million people by the close of 2015, then to 16.8 million people by the end of 2016.  

The study projects that the market share for Viread (tenofovir) will rise from 50 percent in 2013 to 62 percent in 2016, while Retrovir (zidovudine) will see its share drop from 40 percent to 34 percent and Zerit’s (stavudine) market share will decline from 8 percent to 2 percent. Meanwhile, Sustiva (efavirenz) should see its market share increase from 48 percent in 2013 to 63 percent, while Viramune (nevirapine) will lose market share over time. The use of second-line ARVs will increase from 4.4 percent of all HIV meds to 5.0 percent in 2016. There was not enough information to make a projection about how the market share of third-line therapies may change.

To read the aidsmap story, click here.

To read the conference abstract about the upswing in demand, click here.

To read the abstract about cost implications, click here.

Search: Poorer nations, HIV, treatment demand, aidsmap, 20th International AIDS Conference, AIDS 2014, Viread, tenofovir, Retrovir, zidovudine, Zerit, stavudine, Sustiva, efavirenz, Viramune, nevirapine.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Are you buying holiday gifts that raise HIV/AIDS awareness?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.